BIOFRONTERA AG NA ON KONV
BIOFRONTERA AG NA ON KONV/ DE000A4BGGM7 /
B8FK
11/10/2024 19:31:43
|
Diferencia
+0.650
|
Volumen |
Bid20:01:59 |
Ask20:01:59 |
Capitalización de mecado |
Dividendo A. |
P/E Ratio |
2.895EUR
|
+28.95%
|
0 Volumen de negocios: 0.000 |
-Volumen de oferta: - |
-Tamaño/ Volumen/ Formato de Ask: - |
8.69 millonesEUR |
- |
- |
Descripción de negocio
Biofrontera AG is a biopharmaceutical company specializing on the development of drugs and medicinal cosmetics for the treatment of skin diseases and the regenerative care of damaged skin. Headquartered in Leverkusen, Germany, Biofrontera is a publicly listed on the Frankfurt Stock Exchange (Prime Standard) and London Stock Exchange (AIM) – B8F / ISIN: DE 0006046113. In February 2012 Biofrontera launched its prescription drug Ameluz® for the treatment of actinic keratosis on the German market. In other European countries Ameluz® is marketed through local partners. Ameluz® is applied in Photodynamic Therapy requiring a powerful source of red light. For this purpose Biofrontera has developed the BF-RhodoLED® lamp, which was CE marked in November 2012. As cosmeceutical products Biofrontera markets Belixos® for the regenerative care of reddened and inflamed skin. Biofrontera developed a line of cosmeceutical products for damaged skin under the Belixos brand. The product portfolio includes the Belixos® cream, Belixos LIQUID®, Belixos® GEL and DayCare cream Belixos® PROTECT.
Consejo de gestión & Consejo de supervisión
CEO |
- |
Consejo de gestión |
Ludwig Lutter |
Consejo de supervisión |
Wilhelm K. T. Zours, Dr. Jörgen Tielmann, Dr. Heikki Lanckriet, Dr. Helge Lubenow, Karlheinz Schmelig, Prof. Dr. Franca Ruhwedel |
Datos de la empresa
Nombre: |
Biofrontera AG |
Dirección: |
Hemmelrather Weg 201,D-51377 Leverkusen |
Teléfono: |
+49-214-87632-0 |
Fax: |
+49-214-87632-90 |
E-mail: |
info@biofrontera.com
|
Internet: |
www.biofrontera.com |
Industria: |
Healthcare |
Sector: |
Pharmaceutical Industry |
Subsector: |
Pharmaceuticals |
Fin del año financiero: |
31/12 |
Acciones de libre circulación: |
46.41% |
Fecha de OPI: |
- |
Relación con inversores
Nombre: |
Anke zur Mühlen |
IR teléfono: |
- |
IR-fax: |
- |
IR e-mail: |
ir@biofrontera.com
|